You are not logged in.

Saw palmetto supplement use and prostate cancer risk

Bonnar-Pizzorno, Raven M., Littman, Alyson J., Kestin, Mark M. and White, Emily 2006, Saw palmetto supplement use and prostate cancer risk, Nutrition and cancer, vol. 55, no. 1, pp. 21-27, doi: 10.1207/s15327914nc5501_3.

Attached Files
Name Description MIMEType Size Downloads

Title Saw palmetto supplement use and prostate cancer risk
Author(s) Bonnar-Pizzorno, Raven M.
Littman, Alyson J.
Kestin, Mark M.
White, Emily
Journal name Nutrition and cancer
Volume number 55
Issue number 1
Start page 21
End page 27
Publisher Routledge
Place of publication New York, N.Y.
Publication date 2006-07
ISSN 0163-5581
1532-7914
Summary Saw palmetto is an herb used to treat the symptoms of benign prostatic hyperplasia. In vitro studies have found that saw palmetto inhibits growth of prostatic cancer cells and may induce apoptosis. To evaluate whether saw palmetto supplements are associated with a reduced risk of prostate cancer, we conducted a prospective cohort study of 35,171 men aged 50-76 yr in western Washington state. Subjects completed questionnaires between 2000 and 2002 on frequency of use of saw palmetto supplements and saw palmetto-containing multivitamins over the previous 10 yr in addition to other information on supplement intake, medical history, and demographics. Men were followed through December 2003 (mean of 2.3 yr of follow-up) via the western Washington Surveillance, Epidemiology, and End Results cancer registry, during which time 580 developed prostate cancer. Ten percent of the cohort used saw palmetto at least once per week for a year in the 10 yr before baseline. No association was found between this level of use of saw palmetto and risk of prostate cancer development [hazard ratio (HR) = 0.95; 95% confidence interval = 0.74-1.23] or with increasing frequency or duration of use. In this free-living population, use of commercial saw palmetto, which varies widely in dose and constituent ratios, was not associated with prostate cancer risk.
Language eng
DOI 10.1207/s15327914nc5501_3
Field of Research 111299 Oncology and Carcinogenesis not elsewhere classified
HERDC Research category C1.1 Refereed article in a scholarly journal
Copyright notice ©2006, Lawrence Erlbaum Associates
Persistent URL http://hdl.handle.net/10536/DRO/DU:30021875

Document type: Journal Article
Collection: School of Exercise and Nutrition Sciences
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 8 times in TR Web of Science
Scopus Citation Count Cited 7 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 402 Abstract Views, 0 File Downloads  -  Detailed Statistics
Created: Mon, 18 Jan 2010, 11:01:10 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.